- •
Heart failure with preserved ejection fraction (HFPEF) is a common subtype of congestive heart failure for which therapies to improve morbidity and mortality have been limited thus far.
- •
Numerous biomarkers have emerged over the past decade demonstrating prognostic significance in HFPEF, including natriuretic peptides, galectin-3, soluble ST2, and high-sensitivity troponins.
- •
These markers reflect the multiple mechanisms implicated in the pathogenesis of HFPEF, and future research will likely use
Novel Biomarkers in Heart Failure with Preserved Ejection Fraction
Section snippets
Key points
Background
Heart failure (HF) is a global epidemic, defined as an abnormality of cardiac function leading to the inability to deliver oxygen at a rate adequate to meet the requirements of tissues.1 It is truly a clinical syndrome of symptoms and signs resulting from this cardiac abnormality. Over the past decade, further characterization into 2 entities has occurred: HF with preserved ejection fraction (HFPEF) and HF with reduced ejection fraction (HFREF). HFPEF, previously termed diastolic HF,
Pathophysiology
The pathophysiology of HFPEF is controversial and remains poorly understood. Originally, HFPEF was thought to be a primary manifestation of diastolic dysfunction of the left ventricle. However, patients with HFREF are known to also commonly have impaired ventricular relaxation.14, 15 As already mentioned, the primary mechanism of left ventricular (LV) dysfunction is based on structural remodeling and endothelial dysfunction, lending itself to LV stiffness, and increased left atrial pressure.
Therapy
Results from the few randomized controlled trials attempting to find effective therapeutic agents for patients with HFPEF have been limited and mostly discouraging. What has been established as effective includes primarily managing decompensated HFPEF with diuretics to improve fluid status and symptom control. With respect to angiotensin-converting enzyme inhibitors, the PEP-CHF trial demonstrated no significant mortality or rehospitalization benefit with perindopril.30 The CHARM-Preserved
Natriuretic Peptides
The natriuretic peptides (NPs) are the cornerstone biomarker in congestive HF (CHF). Many of the details of the role of NPs are covered in an article by Florea and Anand.35 The Breathing Not Properly trial originally helped establish the role of B-type natriuretic peptide (BNP) in the diagnosis of CHF.36 BNP and the N-terminal prohormone BNP (NT-proBNP) have been shown in numerous trials to be an excellent tool for ruling out CHF as a cause of acute dyspnea. Aside from a strong negative
Future directions
The future of biomarkers and their utility in HF is very promising, starting with the potential for using biomarkers as end points in trials. Biomarkers serve as surrogates for various pathophysiologic mechanisms, and there are potential benefits in using them as trial end points.84 Advantages include the ability to obtain quick and early data, as well as possibly better understand the nature of the disease.76 However, the counterargument against using biomarkers as trial end points includes
References (84)
- et al.
Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective
J Am Coll Cardiol
(1995) - et al.
Epidemiology of diastolic heart failure
Prog Cardiovasc Dis
(2005) - et al.
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry
J Am Coll Cardiol
(2007) - et al.
Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database
J Am Coll Cardiol
(2006) - et al.
Hemodynamic effects of tachycardia in patients with relaxation abnormality: abnormal stroke volume response as an overlooked mechanism of dyspnea associated with tachycardia in diastolic heart failure
J Am Soc Echocardiogr
(2007) - et al.
Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction
J Am Coll Cardiol
(2012) - et al.
Heart failure with a preserved ejection fraction: what is in a name?
J Am Coll Cardiol
(2011) - et al.
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
J Am Coll Cardiol
(2013) - et al.
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Lancet
(2003) - et al.
Biomarkers
Heart Fail Clin
(2012)
Breathing not properly 10 years later: what we have learned and what we still need to learn
J Am Coll Cardiol
Natriuretic peptides
J Am Coll Cardiol
Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular dysfunction
J Am Coll Cardiol
B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction
J Am Coll Cardiol
Troponin elevation in heart failure prevalence, mechanisms, and clinical implications
J Am Coll Cardiol
Galectin-3: an open-ended story
Biochim Biophys Acta
The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients
Clin Chim Acta
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure
J Am Coll Cardiol
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction
J Am Coll Cardiol
Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study
J Am Coll Cardiol
Head-to head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3
J Am Coll Cardiol
Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction
Am J Cardiol
Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase
J Biol Chem
NGAL in acute kidney injury: from serendipity to utility
Am J kidney Dis
Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis
Am J Kidney Dis
Early detection of acute renal failure by serum cystatin C
Kidney Int
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
Eur J Heart Fail
Clinical epidemiology of heart failure
Heart
How do patients with heart failure with preserved ejection fraction die?
Eur J Heart Fail
HFSA 2010 comprehensive heart failure practice guideline
J Card Fail
2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation
Circulation
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and blood Institute
Circulation
Systolic and diastolic heart failure in the community
JAMA
Outcome of heart failure with preserved ejection fraction in a population-based study
N Engl J Med
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey
Eur Heart J
Heart failure with a normal ejection fraction
Heart
New therapeutic options in congestive heart failure: part II
Circulation
How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology
Eur Heart J
Heart failure with normal ejection fraction. Pathophysiology, diagnosis, and treatment
Herz
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota
Circulation
Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle
N Engl J Med
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment
Eur Heart J
Cited by (16)
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF
2018, Journal of the American College of CardiologyCitation Excerpt :Most of these prognostic models were based on clinical and biographical patient characteristics with few biomarkers. The association of some biomarkers that we identified (e.g., NT-proBNP, BUN, ST2, hemoglobin) with mortality or heart failure hospitalization risk in heart failure patients is well known (9,10,30–37), but a differential predictive value in patients who were successfully up-titrated versus those who were not is as yet unknown. This observation may be useful to identify residual heart failure disease and additional treatment targets in heart failure patients.
Value of NLR combined with NT-proBNP on short-term prognosis in patients with chronic heart failure
2019, Chinese Journal of Clinical ResearchBiomarkers in heart failure: the past, current and future
2019, Heart Failure ReviewsST2 in heart failure with preserved and reduced ejection fraction
2019, Scandinavian Cardiovascular JournalHjertesvikt med bevart ejeksjonsfraksjon
2017, Tidsskrift for den Norske Laegeforening